Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Brief Report: Chylothorax and Chylous Ascites During RET Tyrosine Kinase Inhibitor Therapy

Journal of Thoracic Oncology(2022)10.1016/j.jtho.2022.06.008Source: DataRank Database

Brief Report: Chylothorax and Chylous Ascites During RET Tyrosine Kinase Inhibitor Therapy is a research paper published in Journal of Thoracic Oncology (2022). On theSindex it has a DataRank of 0. It has been cited 47 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access47 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (24 grants)Impact (FWCI 8.41)OA: bronzeTopics (38)IDs (PubMed, PMC, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (17)

Christina J. Falcon ORCID,Christine M. Bestvina ORCID,Dazhi Liu ORCID,Lauren A. Kaplanis,Clare Wilhelm ORCID

Live enrichment

PubMed:35788405 PMC:PMC9427698 OpenAlex:https://openalex.org/W4283771713

National Cancer Institute

Grant: P30 CA008748

National Cancer Institute

Grant: 1R01CA251591-01A1

Predicting sensitivity and resistance in RET-driven cancers

NCI NIH HHS

Grant: R01 CA251591

National Institutes of Health

Grant: 2P30CA008748-43

MOUSE GENETICS

LUNGevity Foundation

Silverback Therapeutics

Heron Therapeutics

Northwell Health

Pfizer

Gilead Sciences

Novartis

Relay Therapeutics

Boehringer Ingelheim

Exelixis

Johnson and Johnson

Lunit

Chugai Pharmaceutical

Genentech

AstraZeneca

Merck

National Institutes of Health

GlaxoSmithKline

PharmaMar

Takeda Pharmaceutical Company

FWCI

8.41

Citation Percentile

1.0%

Citation Trend

2022

2023

2024

2025

2026

bronzeLicense: Elsevier Non-Commercial

journalhttp://www.jto.org/article/S1556086422003124/pdf

publisherhttp://www.jto.org/article/S1556086422003124/pdf

journalhttps://doi.org/10.1016/j.jtho.2022.06.008

repositoryhttps://pubmed.ncbi.nlm.nih.gov/35788405

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/9427698

Fields of Study

Lymphatic Disorders and TreatmentsPleural and Pulmonary DiseasesAbdominal vascular conditions and treatments03 medical and health sciences0302 clinical medicineChylothoraxChylous AscitesHumansLung NeoplasmsProtein Kinase InhibitorsProto-Oncogene Proteins c-retRetrospective Studies

MeSH Terms

Chylous AscitesChylothoraxHumansLung NeoplasmsRetrospective StudiesProtein Kinase InhibitorsProto-Oncogene Proteins c-ret

Keywords

MedicineChylous ascitesChylothoraxTyrosine-kinase inhibitorAscitesCancer researchInternal medicineOncologySurgeryCancerThyroid cancerNon–small Cell Lung CancerSelpercatinibRet Tyrosine Kinase InhibitorLung NeoplasmsProto-Oncogene Proteins c-retHumansProtein Kinase InhibitorsRetrospective Studies

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being